Mindstrong Health, a start-up that seeks to combine smartphone useage with mental health diagnostics, has secured 14 million dollars in initial venture capital funding, the company reported. Its series-A funding partners include Foresite Capital, Optum Ventures, One Mine Brain Health Impact Fund and ARCH Venture partners.
The company’s plan is to use smartphone data patterns regarding scrolling and typing to objectively analyze a patient’s mental health and abilities. One of the biggest challenges in many mental health diagnostics today is finding those objective analyses, which can be hard to accomplish in a clinical setting.
Mindstrong Health’s neuropsychiatric treatment and diagnosis platform will be able to process biometric markers clearly and objectively. It can be used to analyze processing speed, attention rates, memory, and other signs of executive function. Each person has a unique way of typing and using their smart phone and the Mindstrong Health platform is designed to use that natural typing and usage to create the biometric data and analyze any changes that may occur.
Results from the Mindstrong Health platform’s clinical trials will be released in the coming months. It is possible that it will be able to deliver consistent, objective measurements of a person’s mental markers in a clear and objective manner that has not been possible with previous doctor-based diagnoses.
Jim Tananbaum, President of Foresite Capital, which is one of the financial partners for the platform and research study, expressed his interest and confidence in the new system being released by Mindstrong Health. He was especially optimistic about the potential for smartphones to pose a global solution for mental illness. The Mindstrong health platform has the potential to offer innovative solutions for that health crisis around the world. Check out Ideamensch to know more.
Jim Tananbaum has previously been recognized as one of Forbes’ Midas Top 100 investors for his investments through Foresite Capital. He has over twenty-five years of experience in modern healthcare and has made major investments in the pharmaceutical industry. Jim holds an M.D from Harvard Medical School and an MBA from the Harvard School of Business, as well as an MS from MIT and a BS and BSEE from Yale.
Check out officialjimtananbaum.com